FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		_															
Name and Address of Reporting Person* Duncan Gregory Scott					2. Issuer Name and Ticker or Trading Symbol Virios Therapeutics, Inc. [VIRI]							5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner						
(Last) (First) (Middle) C/O VIRIOS THERAPEUTICS, INC., 44 MILTON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 04/05/2021								X Officer (give title below) Other (specify below) Chief Executive Officer						
(Street) ALPHARETTA, GA 30009				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person Form filed by More than One Reporting Person							
ALPHAI (City		(State)	(Zip)			Ts	nble I -	- Non	-Dei	rivative !	Securiti	ies Ac	anir	red Disne	osed of, or I	Reneficially	Owne	ed	
(Instr. 3) Date			2. Transaction Date (Month/Day/Year)	Execu any	2A. Deemed Execution Date, if		3. Transact Code (Instr. 8)		(A) or Disposed of (Instr. 3, 4 and 5)		quired l of (D	red 5. Amou Benefici Reported		unt of Securities ially Owned Following d Transaction(s)		6. Own Form	7. of Bo	7. Nature of Indirect Beneficial	
			(Mon	Coo			de	V	Amount	(A) or (D)	Pric	ce	(Instr. 3 a	nd 4)			direct (I	wnership nstr. 4)	
Common Stock		04/05/2021				P			15,675 (1)		\$ 6.17	27	19,579			D			
			Table II -					quire	d, D	isposed	of, or B	enefic	cially	·	OMB cont	trol numbe	er.		
1 77'41 . C	2	2 75 - 41		<i>(e.g.</i> , p		s, wa	arrant	s, opt		s, conver				1 1	0 D : C	0.31 1	c 1	0	I11 NT /
Security	2. Conversion or Exercise Price of Derivative Security	3. Transactio Date (Month/Day/	Year) Execution Da	Year) (Instr. 8)		Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		A U S	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y C F S S C o n(s) (I	0. Ownership Form of Derivative Decurity: Direct (D) or Indirect I) Instr. 4)	Beneficia Ownershi (Instr. 4)		
					Code	V	(A) (D)		Date Exe	-	Expirat Date	ion T	itle	Amount or Number of Shares					
Repor	ting O	wners																	

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Duncan Gregory Scott C/O VIRIOS THERAPEUTICS, INC. 44 MILTON AVENUE ALPHARETTA, GA 30009	X		Chief Executive Officer					

Signatures

/s/ Greg Duncan	04/06/2021				
**Signature of Reporting Person	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 25, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.